BriaCell Therapeutics Corp. (BCTX) Stock Forecast
BCTX analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $150.00 average of analyst targets
- Upside to target
- +4,311.8% from the latest close
- Next earnings
- October 21, 2026
- 52-week range
- $2.74 – $13.79
BCTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BCTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (FY2026) | −$11.45 | −$11.45 | −$11.45 | −$62.19 | +81.6% | 1 |
| Next fiscal year (FY2027) | −$3.40 | −$3.40 | −$3.40 | −$11.45 | +70.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BCTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | — |
| Next fiscal year (FY2027) | $10.1M | $10.1M | $10.1M | +380.9% | 1 |
BCTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BCTX revenue: reported and forecast
BCTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (FY2026) | −$17.70 | −$17.70 | −$11.45 | −$11.45 | −$11.45 | −35.3% | 1 up · 0 down |
| Next fiscal year (FY2027) | −$17.20 | $0.00 | $0.00 | $0.00 | −$3.40 | −80.2% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BCTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BCTX beat in 6 of 9.
What analysts expect from BCTX
The average price target is $150.00, 4,311.8% above the latest close of $3.40. Analysts expect earnings of −$11.45 per share for FY2026, +81.6% from a year earlier. For FY2027 the average estimate is −$3.40 per share on revenue of $10.1 million. BriaCell Therapeutics beat the EPS estimate in 6 of the last 9 quarters.
Related: BCTX income statement, BCTX key metrics, BCTX chart. See the BCTX stock overview for the latest quote and news.
BCTX forecast FAQ
What is BriaCell Therapeutics's price target?
The average analyst price target for BriaCell Therapeutics is $150.00, 4,311.8% above the latest close of $3.40.
What is BriaCell Therapeutics's EPS forecast?
Analysts forecast −$11.45 per share for FY2026 (range −$11.45 to −$11.45); for FY2027 the estimate is −$3.40.
When does BriaCell Therapeutics report earnings?
BriaCell Therapeutics is expected to report results for the quarter ending July 31, 2026 on October 21, 2026.
Does BriaCell Therapeutics usually beat earnings estimates?
BriaCell Therapeutics reported EPS at or above the analyst estimate in 6 of the last 9 quarters.